- Works count
- 781
- Citation count
- 10,545
- H-index
- 53
- i10-index
- 233
Research interests
Publications
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
Blood Advances · 2021 · 10.1182/bloodadvances.2021004292
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
The Lancet Haematology · 2020 · 10.1016/s2352-3026(19)30235-2
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
Blood Advances · 2018 · 10.1182/bloodadvances.2018020305
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
Clinical Lymphoma Myeloma & Leukemia · 2018 · 10.1016/j.clml.2018.03.004
Saturated Fatty Acid Increases Lung Macrophages and Augments House Dust Mite-Induced Airway Inflammation in Mice Fed with High-Fat Diet
Inflammation · 2017 · 10.1007/s10753-017-0550-4
The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells
Blood Cancer Journal · 2017 · 10.1038/bcj.2017.8
2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent
PLoS ONE · 2015 · 10.1371/journal.pone.0141946
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
The Lancet Haematology · 2015 · https://doi.org/10.1016/s2352-3026(15)00196-9
Induction of p53‐mediated transcription and apoptosis by exportin‐1 ( XPO 1) inhibition in mantle cell lymphoma
Cancer Science · 2014 · 10.1111/cas.12430
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Molecular Cancer Therapeutics · 2008 · 10.1158/1535-7163.mct-07-0042
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines
Leukemia Research · 2008 · 10.1016/j.leukres.2007.11.008
ABT‐737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug‐resistance mechanisms
British Journal of Haematology · 2007 · 10.1111/j.1365-2141.2007.06899.x
Zoledronic Acid -a Multiplicity of Anti-Cancer Action
Current Medicinal Chemistry · 2007 · 10.2174/092986707781389600
Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Proceedings of the National Academy of Sciences · 2006 · 10.1073/pnas.0606176103
Comparison of Human Herpes Virus 8 Related Primary Effusion Lymphoma with Human Herpes Virus 8 Unrelated Primary Effusion Lymphoma-Like Lymphoma on the Basis of HIV: Report of 2 Cases and Review of 212 Cases in the Literature
Acta Haematologica · 2006 · 10.1159/000097460
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
Blood · 2006 · 10.1182/blood-2006-03-013250
Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy
International Journal of Cancer · 2005 · 10.1002/ijc.20987
Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer
Journal of Clinical Investigation · 2005 · 10.1172/jci23043
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
Blood · 2005 · 10.1182/blood-2005-06-2209
Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models
Cancer Letters · 2004 · 10.1016/j.canlet.2004.07.010
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines
Lung Cancer · 2004 · 10.1016/j.lungcan.2004.06.003
Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein
Genes to Cells · 2002 · 10.1046/j.1365-2443.2002.00564.x
Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery
Oncogene · 2001 · 10.1038/sj.onc.1204270
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin
Proceedings of the National Academy of Sciences · 1998 · 10.1073/pnas.95.3.1195
GAK: a cyclin G associated kinase contains a tensin/auxilin‐like domain1
FEBS Letters · 1997 · 10.1016/s0014-5793(96)01484-6
Current projects
No projects listed.